Related references
Note: Only part of the references are listed.[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer
Clemens Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT
Frederik A. Verburg et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
Francesco Ceci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
Matthias Eiber et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging
Levent Kabasakal et al.
NUCLEAR MEDICINE COMMUNICATIONS (2015)
[68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice
Thomas Krohn et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
Ali Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Gleason Score at Diagnosis Predicts the Rate of Detection of 18F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients
Marino Cimitan et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
Ali Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
Sotirios Chondrogiannis et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma
Emre Demirci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Axel Heidenreich et al.
EUROPEAN UROLOGY (2014)
A Prospective Pilot Study of 89Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy
Joseph R. Osborne et al.
JOURNAL OF UROLOGY (2014)
Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates
Genliang Lu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2013)
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
A. Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer
Shawn M. Hillier et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Impact of 18F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA Kinetics
Mohsen Beheshti et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Matthias Eder et al.
BIOCONJUGATE CHEMISTRY (2012)
123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy
Shawn M. Hillier et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
Shawn M. Hillier et al.
CANCER RESEARCH (2009)
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis
Sebastian Mannweiler et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients
TD Schmittgen et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Share Paper
